不同剂量微粒化纯化黄酮类组分治疗下肢慢性静脉疾病效果的Meta分析
该Meta分析纳入3项随机对照试验共1924例患者,比较MPFF 1000 mg每日一次与500 mg每日两次的疗效。结果显示两组在患者依从性、疗效、临床不良事件和生活质量评分上均无显著差异,作者认为常规医疗应更常推荐MPFF 1000 mg每日一次。
要点
- MPFF 1000 mg每日一次与500 mg每日两次在患者依从性上无显著差异(SMD 0.049,95%CI 0.048–0.145,p=0.321)。
- 两组在疗效(RR 0.981,95%CI 0.855–1.125,p=0.904)和临床不良事件上无显著差异。
- 两组生活质量评分无显著差异(SMD 0.063,95%CI 0.034–0.160,p=0.203)。
核心结论
- 在有症状的慢性静脉疾病患者中,MPFF 1000 mg每日一次与500 mg每日两次在改善患者依从性、下肢不适、临床不良事件和生活质量评分方面效果相似。
- 作者认为常规医疗应更常推荐MPFF 1000 mg每日一次。
研究设计与样本
- Meta分析,检索MEDLINE、Embase、Science of Web、Cochrane和PubMed数据库及前后向引文,检索时间从数据库建库至2023年3月。
- 纳入3项比较不同剂量MPFF的随机对照试验,无语言或日期限制,共1924例患者(实验组967例,对照组957例)。
- 因纳入研究样本量小,采用逐一排除法进行简单敏感性测试,结果显示研究不影响最终合并结论;使用Cochrane偏倚风险工具评估证据质量。
主要发现
- 在232项研究中,99项符合条件,39项随机对照试验有数据,均为低至中等偏倚风险。
- 患者依从性无显著差异(SMD 0.049,95%CI 0.048–0.145,p=0.321)。
- 疗效无显著差异(RR 0.981,95%CI 0.855–1.125,p=0.904)。
- 临床不良事件和生活质量评分无显著差异(SMD 0.063,95%CI 0.034–0.160,p=0.203)。
临床怎么用
- 作者认为,在有症状的慢性静脉疾病患者中,常规医疗应更常推荐MPFF 1000 mg每日一次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Micronized purified flavonoid fraction (MPFF) is a widely prescribed and extensively investigated venoactive drug (VAD). The standard dosage for MPFF is 500 mg administered twice daily. However, a new daily dose of 1000 mg has just been introduced. OBJECTIVE: This study investigated whether a daily dose of 1000 mg MPFF could be implemented and embraced by the public and still has the same therapeutic effects as conventional pharmaceuticals. METHODS: For this meta-analysis, we searched MEDLINE, Embase, Science of Web, Cochrane, and PubMed databases and forward and backward citations for studies published between database inception and March 2023. Three randomized controlled trials (RCTs) of comparison of different dosages of MPFF to evaluate whether there is a significant difference between them were included, without language or date restrictions. Due to the small sample size of the study included, we conducted a simple sensitivity test using a one-by-one exclusion method, and the results showed that the study did not affect the final consolidation conclusion. The quality of the evidence was assessed using the Cochrane risk-of-bias tool. RESULTS: Out of 232 studies, 99 were eligible and 39 RCTs had data, all with low to moderate bias. Overall, 1924 patients (experimental group: 967, control group: 957) in 3 RCTs met the criteria. There is no significant difference in patient compliance, efficacy, clinical adverse events, and quality of life scores between MPFF 1000 mg once daily and MPFF 500 mg twice daily (standardized mean difference [SMD]: 0.049 [0.048, 0.145], p=0.321, risk ratio [RR]: 0.981 [0.855, 1.125], p=0.904, and SMD: 0.063 [0.034, 0.160], p=0.203). INTERPRETATION: In symptomatic chronic venous disease patients, MPFF 1000 mg once daily and MPFF 500 mg twice daily improve patient compliance, lower limb discomfort, clinical adverse events, and quality of life scores similarly. Regular medical care should recommend MPFF 1000 mg daily more often.Clinical ImpactMicronized purified flavonoid fraction (MPFF) is a popular venoactive medication (VAD) in modern medicine.MPFF is effective in treating lower extremity venous problems.Currently, besides conventional 500 mg tablets, there exist alternative dosage forms such as solutions, chewable tablets, and other novel formulations for MPFF.The excessive frequency and amount of medication may have a negative impact on patient adherence.
引用
- Cui HJ, Wu YF. The Effects of Different Dosages on Micronized Purified Flavonoid Fraction's Treatment of Lower Limb Chronic Venous Disease: A Meta-Analysis. J Endovasc Ther. 2024. PMID: 39066519. doi:10.1177/15266028241262700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。